{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:53:14Z","timestamp":1761709994375,"version":"3.40.5"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Computational Intelligence and Neuroscience"],"published-print":{"date-parts":[[2022,7,22]]},"abstract":"<jats:p>Background. Mizoribine (MZR) is widely used in Asia due to its high safety and low cost, and comparative studies of its safety and efficacy with the first-line drug mycophenolate mofetil (MMF) have been carried out. This paper aimed to compare the efficacy and safety of MZR and MMF in immunosuppressive therapy of renal transplantation by meta-analysis. Methods. We searched randomized controlled trials (RCTs) comparing MZR versus MMF for renal transplantation in PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, WanFang Database, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM). Articles were assessed for their risk of bias using the Cochrane Collaboration. Forest plots and funnel plots were also performed on the included articles. Results. A total of twelve studies with 1103 patients were selected in the analysis. No significant difference were observed between the MZR group and the MMF group for the rate of acute rejection (RR\u2009=\u20091.50, 95% CI 1.11 to 2.01, P\u2009=\u20090.008), patient survival (RR\u2009=\u20091.01, 95% CI 0.99 to 1.03, P\u2009=\u20090.56), graft survival (RR\u2009=\u20091.02, 95% CI 1.00 to 1.04, P\u2009=\u20090.12), leucopenia (RR\u2009=\u20090.69, 95% CI 0.44 to 1.10, P\u2009=\u20090.12), and liver damage (RR\u2009=\u20090.72, 95% CI 0.46 to 1.13, P\u2009=\u20090.15). The MZR group was associated with a lower risk of gastrointestinal disorder (RR\u2009=\u20090.28, 95% CI 0.13 to 0.62, P\u2009=\u20090.002) and cytomegalovirus infection (RR\u2009=\u20090.59, 95% CI 0.42 to 0.84, P\u2009=\u20090.003) but had a higher risk of hyperuricemia (RR 1.79, 95% CI 1.17 to 2.75, P\u2009=\u20090.007). No significant publication bias was observed among included studies. Discussion. MZR is similar to MMF in efficacy, and in terms of safety, MZR has a lower risk of gastrointestinal disorder and cytomegalovirus infection but a higher risk of hyperuricemia.<\/jats:p>","DOI":"10.1155\/2022\/5717068","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T23:35:46Z","timestamp":1658532946000},"page":"1-11","source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis"],"prefix":"10.1155","volume":"2022","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[{"name":"Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"UrinarySurgery, Southern Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Yin","sequence":"additional","affiliation":[{"name":"Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengguang","family":"Xu","sequence":"additional","affiliation":[{"name":"Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekai","family":"Chen","sequence":"additional","affiliation":[{"name":"Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1621-341X","authenticated-orcid":true,"given":"Wingkeung","family":"Yiu","sequence":"additional","affiliation":[{"name":"Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"9185","key":"1","first-page":"1147","article-title":"Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK","volume":"354","author":"P. J. Morris","year":"2019","journal-title":"Lancet (North American Edition)"},{"issue":"1","key":"2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2017.07.017","article-title":"The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic Review - ScienceDirect","volume":"73","author":"R. Boissier","year":"2018","journal-title":"European Urology"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00910.x"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12402"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.12423"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8815-17"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2009.2836"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1645\/13-278.1"},{"key":"9","first-page":"358","article-title":"Pharmacokinetics of mycophenolate mofetil metabolites in older patients on the seventh day after renal transplantation article in press","volume":"53","author":"J. Sobiak","year":"2021","journal-title":"Transplantation Proceedings"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.03.052"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.10.018"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2021.04.001"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2433-8"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.291"},{"issue":"01","key":"15","first-page":"6","article-title":"Application of mizoribine in cadaveric renal transplantation","volume":"18","author":"A. Ming","year":"2003","journal-title":"Journal of Clinical Urology"},{"issue":"1","key":"16","first-page":"14","article-title":"Application of mizoribine in clinical kidney transplantation","volume":"29","author":"Q. Yan","year":"2008","journal-title":"Chin J Organ Transplant"},{"issue":"7","key":"17","first-page":"595","article-title":"Comparison of two triple immunosuppressive regimens of mizoribine and mycophenolate mofetil in renal transplant patients","volume":"19","author":"S. Han","year":"2010","journal-title":"Chin J New Drugs"},{"issue":"1","key":"18","first-page":"18","article-title":"Efficacy and safety of mizroribine in early postoperative renal transplantations","volume":"33","author":"L. Chen","year":"2012","journal-title":"Chin J Organ Transplant"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.12.028"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0780-1"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-012-0669-4"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.10.061"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.12.117"},{"issue":"5","key":"24","first-page":"518","article-title":"A prospective randomized, comparative trial of high-dose mizoribine versus mycophenolate mofetil in combination with tacrolimus and basiliximab for living donor renal transplant: a multicenter trial","volume":"14","author":"H. Ishida","year":"2016","journal-title":"Experimental and Clinical Transplantation :Official Journal of the Middle East Society for Organ Transplantation"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.03.014"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.05.022"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000001129"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000001487"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.11.073"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.12.029"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1186\/s13568-019-0934-y"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-021-00713-0"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.10.030"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.01.014"},{"issue":"10","key":"35","first-page":"1102","article-title":"Efficacy and safety of mizoribine and mycophenolate mofetil after renal transplantation:a Meta-analysis","volume":"38","author":"N. Li","year":"2018","journal-title":"Chinese Journal of Hospital Pharmacy"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.12659\/aot.923536"},{"issue":"12","key":"37","first-page":"723","article-title":"Clinical application of mizoribine in minimizing virus infection risk in renal graft recipients","volume":"27","author":"Y. Qian","year":"2006","journal-title":"Chin J Organ Transplant"},{"issue":"7","key":"38","first-page":"435","article-title":"The conversion of mizoribine to treat myelosuppression after renal transplantation","volume":"19","author":"J. Ao","year":"2004","journal-title":"Journal of Clinical Urology"}],"container-title":["Computational Intelligence and Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cin\/2022\/5717068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cin\/2022\/5717068.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cin\/2022\/5717068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T23:36:06Z","timestamp":1658532966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cin\/2022\/5717068\/"}},"subtitle":[],"editor":[{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":38,"alternative-id":["5717068","5717068"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5717068","relation":{},"ISSN":["1687-5273","1687-5265"],"issn-type":[{"type":"electronic","value":"1687-5273"},{"type":"print","value":"1687-5265"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}